Niagen Bioscience Inc
NAGEConsumer Defensive·Packaged Foods·USA·Micro·NASD·Nov 11 • 3:59 PM ET
2.10-0.06 (-2.56%)
2026-11-12 05:16 CET
Market cap
165.92 USD m
Revenue, TTM
122.29 USD m
Net income, TTM
10.24 USD m
Free cash flow, TTM
4.52 USD m
EPS diluted, TTM
0.12
P/E
17.39
Price
NAGE against its 20, 50 and 200-day averages2050200missearnings
71.2% under the 52-week high of 7.28 on 13 Nov 2025. 52-week low 2.04 on 6 Nov 2026. Last 15 sessions, 27.3% high to low
Volume 0.75× normal · the line is the 50-bar volume average
Profile
NAGE52-week range, 1% of the way up
2.047.28
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, Analytical Reference Standards and Services, and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The Pharmaceuticals segment focuses on the pharmaceutical development of NAD precursor portfolio for potential therapeutic applications in rare diseases. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
| Index | RUT |
|---|---|
| Employees | 117 |
| IPO | Jun 24, 2008 |
| Beta | 2.09 |
| ATR, 14d | 0.13 |
| Rel volume | 0.75 |
| Short float | 8.36% |
| Insider own | 34.33% |
| Inst own | 41.03% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | 165.91M |
| Enterprise Value | 98.48M |
| Income | 10.24M |
| Sales | 122.29M |
| Book/sh | 1.05 |
| Cash/sh | 0.88 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | 0.00% |
| Employees | 117 |
| IPO | Jun 24, 2008 |
Ratios
| P/E | 17.39 |
|---|---|
| Forward P/E | 52.38 |
| PEG | - |
| P/S | 1.36 |
| P/B | 1.99 |
| P/C | 2.39 |
| P/FCF | 36.71 |
| EV/EBITDA | 20.18 |
| EV/Sales | 0.81 |
| Quick Ratio | 4.71 |
| Current Ratio | 5.93 |
| Debt/Eq | 0.03 |
| LT Debt/Eq | 0.02 |
| Option/Short | Yes / Yes |
Earnings
| EPS (ttm) | 0.12 |
|---|---|
| EPS next Y | 0.04 |
| EPS next Q | -0.02 |
| EPS this Y | -71.67% |
| EPS next Y | -29.41% |
| EPS next 5Y | -13.38% |
| EPS past 3/5Y | - - |
| Sales past 3/5Y | 21.56% 16.91% |
| EPS Y/Y TTM | -50.75% |
| Sales Y/Y TTM | -1.94% |
| EPS Q/Q | -128.03% |
| Sales Q/Q | -19.99% |
| Earnings | Nov 04 AMC |
| EPS/Sales Surpr. | -49.25% -10.02% |
Ownership
| Insider Own | 34.33% |
|---|---|
| Insider Trans | 0.00% |
| Inst Own | 41.03% |
| Inst Trans | -7.46% |
| ROA | 9.90% |
| ROE | 13.32% |
| ROIC | 12.14% |
| Gross Margin | 63.86% |
| Oper. Margin | 2.28% |
| Profit Margin | 8.37% |
| SMA20 | -12.32% |
| SMA50 | -22.51% |
| SMA200 | -44.26% |
| Trades | - |
Technical
| Shs Outstand | 79.03M |
|---|---|
| Shs Float | 52.01M |
| Short Float | 8.36% |
| Short Ratio | 8.70 |
| Short Interest | 4.35M |
| 52W High | 7.28 -71.22% |
| 52W Low | 2.04 2.95% |
| Volatility | 7.73% 4.82% |
| ATR (14) | 0.13 |
| RSI (14) | 35.53 |
| Beta | 2.09 |
| Rel Volume | 0.75 |
| Avg Volume | 499.64K |
| Volume | 373,422 |
Performance
| Perf Week | -16.87% |
|---|---|
| Perf Month | -18.80% |
| Perf Quarter | -31.31% |
| Perf Half Y | -44.28% |
| Perf YTD | -67.06% |
| Perf Year | -70.74% |
| Perf 3Y | 52.92% |
| Perf 5Y | -65.99% |
| Perf 10Y | -29.70% |
| Recom | 1.00 |
| Target Price | 10.67 |
| Prev Close | 2.15 |
| Price | 2.10 |
| Change % | -2.56% |
Analyst ratings
latest 9 of 9| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| May 27, 2025 | Initiated | CCanaccord Genuity | Buy | $13 | +520.5% |
| Aug 16, 2022 | Downgrade | OOppenheimer | Outperform → Perform | ||
| Aug 11, 2022 | Downgrade | RB. Riley Securities | Buy → Neutral | $6 → $2.40 | +14.6% |
| Mar 08, 2022 | Initiated | RROTH Capital | Buy | $7 | +234.1% |
| Oct 16, 2019 | Initiated | OOppenheimer | Outperform | $6 | +186.4% |
| Feb 14, 2019 | Initiated | BB. Riley FBR | Buy | $7 | +234.1% |
| Nov 27, 2017 | Resumed | HH.C. Wainwright | Buy | $6 → $8 | +281.9% |
| Sep 25, 2017 | Initiated | LLadenburg Thalmann | Buy | $7 | +234.1% |
| Jan 03, 2017 | Initiated | RRodman & Renshaw | Buy | $6 | +186.4% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| NATR | Nature's Sunshine Products Inc | 178.66M |
| USNA | Usana Health Sciences Inc | 237.42M |
| LFVN | Lifevantage Corp | 59.86M |
| FTLF | FitLife Brands Inc | 78.13M |
| HLF | Herbalife Ltd | 1.63B |
| NUS | Nu Skin Enterprises Inc | 189.36M |
| BRBR | Bellring Brands Inc | 1.16B |
| SMPL | Simply Good Foods Co | 1.10B |
| MED | Medifast Inc | 146.83M |
| BYND | Beyond Meat Inc | 108.33M |
Insider trading
3 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Fried Robert N | Chief Executive Officer | Apr 24 '26 | Option Exercise | 2.61 | 20,000 | 52,200 | 1,058,981 | Apr 27 08:33 AM |
| Pamir Ozan | Chief Financial Officer | Nov 14 '25 | Buy | 6.81 | 4,465 | 30,406 | 7,372 | Nov 17 08:23 AM |
| Pamir Ozan | Chief Financial Officer | Nov 14 '25 | Buy | 6.85 | 2,220 | 15,210 | 2,220 | Nov 17 08:23 AM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 687.42B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.38B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.47B |
| VDC | Vanguard Consumer Staples ETF | AUM: 8.36B |
| IWO | iShares Russell 2000 Growth ETF | AUM: 14.06B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.75B |
| SCHA | Schwab U.S. Small-Cap ETF | AUM: 22.25B |
| SFLO | VictoryShares Small Cap Free Cash Flow ETF | AUM: 889.00M |
| IWC | iShares Micro-Cap ETF | AUM: 1.22B |
| ETHO | Amplify Etho Climate Leadership U.S. ETF | AUM: 194.75M |
News
latest 14 of 200- Niagen Bioscience Announces Participation in Upcoming Investor Conferences (Business Wire) +10.14%
- Niagen Bioscience Matches On EPS, But A 20% Revenue Drop And Fading Guidance Push The Story To 2027 (Earnings Whispers) +6.78% -16.47%
- Niagen Bioscience: Q3 Earnings Snapshot (Associated Press)
- Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results (Business Wire)
- Niagen Bioscience Faces A Proof Test As Marketing Costs Swallow Profits In An Investment Year (Earnings Whispers)
- Niagen Bioscience Launches Niagen Plus Liquid At-Home Injections to Support Telehealth Expansion (Business Wire)
- Niagen Bioscience Makes Skincare a Permanent Tru Niagen Category, Launching Dermatologist-Tested Niagen NanoCloud as a Core Tru Niagen Product (Business Wire)
- Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026 (Business Wire)
- Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN) (Business Wire)
- Niagen Bioscience to Present at LD Micro 20th Annual Main Event (Business Wire)
- Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better." a New Campaign for its Niagen Brand Featuring Legendary Surfer Kelly Slater (Business Wire) -8.22%
- Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial (Business Wire)
- Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes (Business Wire)
- Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth (Business Wire)
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-11-04 | -0.010 | -0.007 | -0.010 | 27.19 | 30.22 | 6 |
| 2026Q2 | 2026-08-04 | 0.010 | 0.008 | 0.012 | 29.79 | 30.53 | 6 |
| 2026Q1 | 2026-05-06 | 0.070 | 0.068 | 0.075 | 31.47 | 31.03 | 5 |
| 2025Q4 | 2026-03-04 | 0.050 | 0.022 | 0.049 | 33.84 | 31.70 | 5 |
| 2025Q3 | 2025-11-04 | 0.050 | 0.018 | 0.053 | 33.99 | 31.20 | 4 |
| 2025Q2 | 2025-08-06 | 0.040 | 0.009 | 0.042 | 31.12 | 28.31 | 4 |
| 2025Q1 | 2025-05-07 | 0.073 | 0.020 | 0.061 | 30.48 | 27.08 | 4 |
| 2024Q4 | 2025-03-04 | 0.090 | 0.023 | 0.088 | 29.13 | 26.78 | 4 |
| 2024Q3 | 2024-10-31 | 0.030 | 0.006 | 0.024 | 25.58 | 24.03 | 4 |
| 2024Q2 | 2024-08-07 | 0.000 | -0.020 | 0.000 | 22.74 | 23.33 | 4 |
| 2024Q1 | 2024-05-08 | -0.010 | -0.020 | -0.007 | 22.15 | 23.48 | 4 |
| 2023Q4 | 2024-03-06 | 0.000 | -0.023 | 0.002 | 21.20 | 20.81 | 4 |
| 2023Q3 | 2023-11-08 | 0.005 | -0.030 | -0.013 | 19.50 | 20.30 | 5 |
| 2023Q2 | 2023-08-09 | -0.030 | -0.040 | -0.029 | 20.32 | 19.42 | 5 |
| 2023Q1 | 2023-05-10 | -0.030 | -0.047 | -0.025 | 22.56 | 19.41 | 6 |
| 2022Q4 | 2023-03-08 | -0.020 | -0.025 | -0.019 | 21.00 | 21.14 | 6 |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2019FY | -0.520 | -0.516 | -0.563 | 46.29 | 46.17 |
| 2020FY | -0.330 | -0.318 | -0.326 | 59.26 | 59.16 |
| 2021FY | -0.400 | -0.427 | -0.404 | 67.45 | 68.33 |
| 2022FY | -0.240 | -0.250 | -0.237 | 72.05 | 72.34 |
| 2023FY | -0.070 | -0.080 | -0.066 | 83.57 | 83.20 |
| 2024FY | 0.110 | 0.040 | 0.109 | 99.60 | 97.19 |
| 2025FY | 0.200 | 0.182 | 0.200 | 129.42 | 127.29 |
| 2026FY | - | 0.057 | - | - | 118.55 |
| 2027FY | - | 0.040 | - | - | 135.53 |
| 2028FY | - | 0.130 | - | - | 156.88 |
| 2029FY | - | 0.340 | - | - | 209.7 |
| 2030FY | - | 0.410 | - | - | 233.1 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2026Q4 | S | 2026-11-05 | 6 | 0 | 6 | 29.93 | 29.50 | 30.38 |
| 2026Q4 | S | 2026-11-04 | 6 | 0 | 5 | 33.24 | 29.50 | 39.00 |
| 2026Q4 | S | 2026-11-03 | 6 | 0 | 5 | 33.24 | 29.50 | 39.00 |
| 2026Q4 | S | 2026-11-02 | 6 | 0 | 4 | 34.24 | 29.50 | 39.00 |
| 2026Q4 | S | 2026-10-30 | 6 | 0 | 3 | 34.89 | 29.50 | 39.00 |
| 2026Q4 | S | 2026-10-28 | 5 | 0 | 2 | 35.86 | 29.50 | 39.00 |
| 2026Q4 | S | 2026-10-19 | 6 | 0 | 1 | 36.83 | 29.50 | 40.80 |
| 2026Q4 | S | 2026-10-09 | 6 | 0 | 4 | 36.83 | 29.50 | 40.80 |
| 2026Q4 | S | 2026-10-03 | 6 | 0 | 4 | 38.55 | 36.00 | 40.80 |
| 2026Q4 | S | 2026-09-24 | 6 | 1 | 5 | 38.55 | 36.00 | 40.80 |
| 2026Q4 | S | 2026-09-23 | 6 | 1 | 5 | 38.54 | 36.00 | 40.80 |
| 2026Q4 | S | 2026-08-11 | 6 | 1 | 5 | 38.55 | 36.00 | 40.80 |
| 2026Q4 | S | 2026-08-05 | 6 | 1 | 5 | 38.54 | 36.00 | 40.80 |
| 2026Q4 | S | 2026-07-29 | 6 | 2 | 2 | 41.77 | 38.79 | 45.90 |
Estimate history
| EPS, annual | -0.378 | -0.606 | -0.563 | -0.326 | -0.404 | -0.237 | -0.066 | 0.109 | 0.203 | 0.1205 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| EPS, quarterly | 0.024 | 0.088 | 0.061 | 0.042 | 0.053 | 0.049 | 0.075 | 0.012 | -0.015 | |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
| Sales, annual | 21.201 | 31.557 | 46.291 | 59.257 | 67.449 | 72.05 | 83.57 | 99.597 | 129.423 | 122.29 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| Sales, quarterly | 25.58 | 29.125 | 30.481 | 31.117 | 33.986 | 33.839 | 31.474 | 29.785 | 27.192 | |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
| Shares, annual | 54.697 | 55.089 | 59.562 | 61.881 | 68.126 | 74.567 | 74.981 | 77.33 | 79.714 | 79.03 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | MRQ |
| Shares, quarterly | 76.027 | 77.33 | 78.433 | 79.586 | 79.639 | 79.714 | 79.457 | 78.908 | 79.03 | |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 122.29 | 129.42 | 99.60 | 83.57 | 72.05 | 67.45 | 59.26 | 46.29 | 31.56 |
| Cost of Goods Sold Incl. D&A | 44.19 | 46.23 | 38.01 | 32.79 | 29.25 | 25.96 | 23.98 | 20.52 | 15.50 |
| Gross Profit | 78.10 | 83.19 | 61.59 | 50.78 | 42.80 | 41.49 | 35.27 | 25.77 | 16.05 |
| Selling, General and Administrative Excl. Other | 75.31 | 68.89 | 53.86 | 52.68 | 51.52 | 52.16 | 46.53 | 45.64 | 49.15 |
| Research and Development | 6.50 | 6.33 | 6.02 | 4.96 | 4.83 | 3.83 | 3.73 | 4.42 | 5.48 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.07 |
| Operating Income | 2.79 | 14.30 | 7.73 | -1.90 | -8.73 | -10.67 | -11.25 | -20.00 | -33.17 |
| Interest Expense | - | - | - | - | - | 0.06 | 0.07 | 0.85 | 0.08 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 3.70 | 9.90 | 16.40 | 8.60 | 11.30 | 0.00 |
| Net Income Before Taxes | 11.05 | 18.19 | 8.86 | -4.94 | -16.54 | -27.13 | -19.93 | -32.15 | -33.32 |
| Income Taxes | 0.81 | 0.81 | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | 10.24 | 17.38 | 8.55 | -4.94 | -16.54 | -27.13 | -19.93 | -32.15 | -33.32 |
| Net Income From Continuing Operations | 10.24 | 17.38 | 8.55 | -4.94 | -16.54 | -27.13 | -19.93 | -32.15 | -33.32 |
| Net Income | 10.24 | 17.38 | 8.55 | -4.94 | -16.54 | -27.13 | -19.93 | -32.15 | -33.32 |
| EPS (Recurring) | 0.13 | 0.20 | 0.11 | -0.03 | -0.14 | -0.23 | -0.23 | -0.42 | -0.61 |
| EPS (Basic, Before Extraordinaries) | 0.13 | 0.22 | 0.11 | -0.07 | -0.24 | -0.40 | -0.33 | -0.56 | -0.61 |
| EPS (Diluted) | 0.12 | 0.20 | 0.11 | -0.07 | -0.24 | -0.40 | -0.33 | -0.56 | -0.61 |
| EBITDA | 4.88 | 15.75 | 9.21 | -0.19 | -6.84 | -9.05 | -9.74 | -18.48 | -32.33 |
| Non-Operating Income (Expense) | 8.26 | 3.90 | 1.13 | 0.66 | 2.09 | 0.00 | 0.00 | 0.00 | -0.07 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 5.62 | 4.79 | 2.89 | 4.75 | 5.74 | 6.20 | 6.94 | 7.17 | 6.37 |
| Price To Earnings Ratio | 17.39 | 17.39 | 280.69 | - | - | - | - | - | - |
| Price To Sales Ratio | 1.89 | 4.20 | 4.16 | 1.28 | 1.63 | 3.73 | 4.95 | 5.31 | 5.98 |
| Gross Margin | 63.86 | 64.28 | 61.84 | 60.76 | 59.40 | 61.51 | 59.53 | 55.67 | 50.88 |
| Operating Margin | 2.28 | 11.05 | 7.76 | -2.27 | -12.11 | -15.82 | -18.99 | -43.20 | -105.12 |
| Net Margin | 8.37 | 13.43 | 8.58 | -5.91 | -22.96 | -40.22 | -33.62 | -69.45 | -105.57 |
| Shares Outstanding | 79.03 | 79.71 | 77.33 | 74.98 | 74.57 | 68.13 | 61.88 | 59.56 | 55.09 |
| Market Capitalization | 165.92 | 165.92 | 405.21 | 107.43 | 125.11 | 255.41 | 296.58 | 256.78 | 158.10 |
Income statement, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 27.19 | 29.79 | 31.47 | 33.84 | 33.99 | 31.12 | 30.48 | 29.12 |
| Cost of Goods Sold Incl. D&A | 10.09 | 10.47 | 11.50 | 12.13 | 12.06 | 10.89 | 11.15 | 10.93 |
| Gross Profit | 17.11 | 19.31 | 19.98 | 21.70 | 21.93 | 20.23 | 19.33 | 18.20 |
| Selling, General and Administrative Excl. Other | 18.69 | 18.61 | 18.40 | 19.60 | 17.69 | 17.04 | 14.56 | 11.09 |
| Research and Development | 1.80 | 1.51 | 1.48 | 1.71 | 1.79 | 1.57 | 1.26 | 1.31 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -1.59 | 0.70 | 1.58 | 2.10 | 4.24 | 3.19 | 4.77 | 7.11 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -1.17 | 1.07 | 6.74 | 4.42 | 4.80 | 3.74 | 5.23 | 7.48 |
| Income Taxes | 0.00 | 0.11 | 0.42 | 0.29 | 0.22 | 0.13 | 0.17 | 0.30 |
| Consolidated Net Income | -1.17 | 0.96 | 6.32 | 4.13 | 4.58 | 3.61 | 5.06 | 7.18 |
| Net Income From Continuing Operations | -1.17 | 0.96 | 6.32 | 4.13 | 4.58 | 3.61 | 5.06 | 7.18 |
| Net Income | -1.17 | 0.96 | 6.32 | 4.13 | 4.58 | 3.61 | 5.06 | 7.18 |
| EPS (Recurring) | -0.01 | 0.01 | 0.07 | 0.05 | 0.05 | 0.04 | 0.06 | 0.09 |
| EPS (Basic, Before Extraordinaries) | -0.01 | 0.01 | 0.08 | 0.05 | 0.06 | 0.05 | 0.07 | 0.09 |
| EPS (Diluted) | -0.01 | 0.01 | 0.07 | 0.05 | 0.05 | 0.04 | 0.06 | 0.09 |
| EBITDA | -1.30 | 1.17 | 2.04 | 2.97 | 4.43 | 3.38 | 4.97 | 7.47 |
| Non-Operating Income (Expense) | 0.41 | 0.37 | 5.16 | 2.32 | 0.56 | 0.55 | 0.46 | 0.37 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 1.52 | 1.36 | 1.36 | 1.38 | 1.39 | 1.18 | 0.85 | 0.59 |
| Price To Earnings Ratio | 17.39 | 14.61 | 21.56 | 26.13 | 43.46 | 83.44 | 65.53 | 280.69 |
| Price To Sales Ratio | 1.89 | 2.04 | 2.86 | 4.15 | 6.48 | 10.69 | 5.32 | 4.35 |
| Gross Margin | 62.90 | 64.84 | 63.47 | 64.14 | 64.52 | 65.00 | 63.42 | 62.48 |
| Operating Margin | -5.84 | 2.35 | 5.01 | 6.21 | 12.46 | 10.24 | 15.66 | 24.42 |
| Net Margin | -4.31 | 3.23 | 20.07 | 12.21 | 13.47 | 11.60 | 16.61 | 24.65 |
| Shares Outstanding | 79.03 | 78.91 | 79.46 | 79.71 | 79.64 | 79.59 | 78.43 | 77.33 |
| Market Capitalization | 165.92 | 254.07 | 353.15 | 507.57 | 744.10 | 1,135.07 | 536.48 | 405.21 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY | 2017FY |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 64.79 | 44.66 | 27.32 | 20.44 | 28.22 | 16.70 | 18.81 | 22.62 | 45.39 |
| Short Term Receivables | 9.74 | 7.77 | 5.23 | 8.48 | 5.23 | 2.69 | 2.17 | 5.09 | 5.34 |
| Inventories | 20.42 | 9.19 | 14.53 | 14.68 | 13.60 | 11.68 | 11.54 | 8.25 | 5.80 |
| Other Current Assets | 1.85 | 2.48 | 2.45 | 2.97 | 1.86 | 1.15 | 1.00 | 0.58 | 0.66 |
| Total Current Assets | 96.81 | 64.10 | 49.53 | 46.57 | 48.91 | 32.22 | 33.52 | 36.53 | 57.18 |
| Net Property, Plant & Equipment | 3.52 | 3.45 | 4.54 | 6.32 | 7.36 | 4.43 | 4.66 | 3.58 | 2.87 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.32 | 0.00 |
| Long-Term Note Receivable | - | - | - | - | - | - | - | 0.00 | 0.75 |
| Intangible Assets | 5.66 | 0.36 | 0.51 | 0.67 | 0.86 | 1.08 | 1.31 | 1.55 | 1.65 |
| Other Assets | 0.42 | 0.37 | 0.38 | 0.50 | 0.72 | 0.62 | 0.76 | 0.24 | 0.27 |
| Total Assets | 106.41 | 68.28 | 54.96 | 54.06 | 57.84 | 38.36 | 40.25 | 42.23 | 62.72 |
| Short Term Debt Incl. Current Port. of LT Debt | 1.00 | 0.99 | 0.70 | 0.70 | 0.55 | 0.62 | 0.85 | 0.17 | 0.20 |
| Accounts Payable | 10.80 | 8.53 | 10.23 | 9.68 | 10.42 | 9.45 | 9.63 | 9.55 | 3.72 |
| Other Current Liabilities | 8.12 | 8.43 | 9.69 | 7.49 | 6.64 | 6.41 | 4.58 | 4.72 | 4.17 |
| Total Current Liabilities | 19.92 | 17.95 | 20.62 | 17.87 | 17.61 | 16.48 | 15.06 | 14.44 | 8.09 |
| Long Term Debt | 1.81 | 1.66 | 2.58 | 3.56 | 4.15 | 1.02 | 0.87 | 0.14 | 0.31 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 8.14 | 2.58 | 3.31 | 3.96 | 4.35 | 4.44 | 3.87 | 0.48 | 0.49 |
| Total Liabilities | 29.87 | 22.18 | 26.51 | 25.39 | 26.11 | 21.93 | 19.80 | 15.05 | 8.89 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 76.53 | 46.09 | 28.46 | 28.67 | 31.73 | 16.42 | 20.45 | 27.18 | 53.83 |
| Total Shareholders Equity | 76.53 | 46.09 | 28.46 | 28.67 | 31.73 | 16.42 | 20.45 | 27.18 | 53.83 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 76.53 | 46.09 | 28.46 | 28.67 | 31.73 | 16.42 | 20.45 | 27.18 | 53.83 |
| Total Liabilities & Stockholders Equity | 106.41 | 68.28 | 54.96 | 54.06 | 57.84 | 38.36 | 40.25 | 42.23 | 62.72 |
| Book Value Per Share | 0.96 | 0.60 | 0.38 | 0.38 | 0.47 | 0.27 | 0.34 | 0.49 | 0.98 |
| Tangible Book Value Per Share | 0.89 | 0.59 | 0.37 | 0.38 | 0.45 | 0.25 | 0.32 | 0.47 | 0.95 |
| Full-Time Employees | 117 | 104 | 106 | 113 | 115 | 110 | 110 | 100 | 74 |
| Price to Book Ratio | 1.99 | 11.74 | 3.92 | 5.45 | 8.03 | 18.09 | 12.56 | 6.95 | 8.30 |
| Return on Assets | 19.90 | 13.88 | -9.06 | -29.56 | -56.40 | -50.70 | -77.95 | -63.49 | -40.08 |
| Return on Equity | 28.35 | 22.94 | -17.29 | -54.77 | -112.68 | -108.09 | -135.01 | -82.25 | -51.81 |
| Return on Invested Capital | 22.19 | 17.91 | -15.91 | -51.31 | -75.61 | -114.24 | -150.85 | -121.97 | -31.11 |
| Quick Ratio | 3.83 | 3.06 | 1.70 | 1.78 | 2.00 | 1.25 | 1.46 | 1.96 | 6.35 |
| Current Ratio | 4.86 | 3.57 | 2.40 | 2.61 | 2.78 | 1.96 | 2.23 | 2.53 | 7.07 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | 10.24 | 17.38 | 8.55 | -4.94 | -16.54 | -27.13 | -19.93 | -32.15 | -33.32 |
| Depreciation | 1.74 | 1.45 | 1.48 | 1.71 | 1.88 | 1.63 | 1.51 | 1.52 | 0.84 |
| Other Funds (Non Cash) | 0.45 | 2.90 | -1.11 | 5.71 | 5.80 | 6.24 | 4.80 | 9.71 | 6.36 |
| Funds from Operations | 12.42 | 21.73 | 8.92 | 2.48 | -8.86 | -19.26 | -13.61 | -20.91 | -26.12 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -7.59 | -8.30 | 3.13 | 4.56 | -6.32 | -5.01 | 2.96 | -0.20 | 5.19 |
| Cash from Operating Activities | 4.83 | 13.44 | 12.06 | 7.04 | -15.18 | -24.27 | -10.65 | -21.12 | -20.93 |
| Capital Expenditures | -0.30 | -0.29 | -0.16 | -0.15 | -0.33 | -0.41 | -0.14 | -0.80 | -1.45 |
| Net Assets From Acquisitions | -0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Sale of Fixed Assets and Businesses | 5.80 | 0.00 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | -0.32 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | -0.32 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.55 | - |
| Cash from Investing Activities | 5.00 | -0.29 | -0.14 | -0.14 | -0.33 | -0.41 | -0.17 | -0.25 | -1.77 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | -4.56 | 7.00 | 5.43 | 0.00 | 7.75 | 36.23 | 8.97 | 7.84 | 0.12 |
| Repurchase of Common Pref Stock | -5.37 | -0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.40 |
| Sale of Common Pref Stock | 0.81 | 7.25 | 5.43 | 0.00 | 7.75 | 36.23 | 8.97 | 7.84 | 0.53 |
| Proceedsfrom Stock Options | 0.07 | 0.00 | 0.00 | 0.00 | 7.75 | 26.74 | 4.86 | 6.77 | 0.00 |
| Issuance or Reduction of Debt, Net | -0.00 | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 | -0.27 | 9.72 | -0.20 |
| Change in Long Term Debt | -0.00 | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 | -0.27 | -0.28 | -0.20 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -0.00 | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 | -0.27 | -0.28 | -0.20 |
| Net Financing Active Other Cash Flow | -0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | -0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -4.61 | 6.98 | 5.42 | -0.01 | 7.73 | 36.20 | 8.70 | 17.56 | -0.07 |
| Net Change in Cash | 5.22 | 20.13 | 17.34 | 6.88 | -7.78 | 11.52 | -2.12 | -3.80 | -22.77 |
| Free Cash Flow | 4.52 | 13.14 | 11.89 | 6.89 | -15.51 | -24.68 | -10.77 | -21.86 | -22.25 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price to Free Cash Flow | 51.09 | 41.34 | 34.85 | 15.55 | - | - | - | - | - |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 69.51 | 66.74 | 66.55 | 64.79 | 64.29 | 60.47 |
| Short Term Receivables | 6.84 | 8.58 | 13.07 | 9.74 | 8.51 | 9.66 |
| Inventories | 20.52 | 20.64 | 24.02 | 20.42 | 18.79 | 14.41 |
| Other Current Assets | 3.34 | 1.83 | 1.49 | 1.85 | 2.03 | 2.14 |
| Total Current Assets | 100.22 | 97.79 | 105.12 | 96.81 | 93.62 | 86.68 |
| Net Property, Plant & Equipment | 2.87 | 3.09 | 3.32 | 3.52 | 3.86 | 4.16 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 5.14 | 5.31 | 5.49 | 5.66 | 0.25 | 0.28 |
| Other Assets | 0.47 | 0.41 | 0.41 | 0.42 | 0.42 | 0.41 |
| Total Assets | 108.69 | 106.59 | 114.33 | 106.41 | 98.14 | 91.53 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.80 | 0.92 | 1.03 | 1.00 | 0.98 | 0.96 |
| Accounts Payable | 11.50 | 9.44 | 13.28 | 10.80 | 12.74 | 13.68 |
| Other Current Liabilities | 4.61 | 4.69 | 8.52 | 8.12 | 8.99 | 7.68 |
| Total Current Liabilities | 16.91 | 15.05 | 22.82 | 19.92 | 22.71 | 22.33 |
| Long Term Debt | 1.28 | 1.41 | 1.54 | 1.81 | 2.08 | 2.33 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 7.43 | 7.60 | 7.63 | 8.14 | 2.67 | 2.67 |
| Total Liabilities | 25.62 | 24.06 | 32.00 | 29.87 | 27.46 | 27.33 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 83.07 | 82.53 | 82.33 | 76.53 | 70.68 | 64.19 |
| Total Shareholders Equity | 83.07 | 82.53 | 82.33 | 76.53 | 70.68 | 64.19 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 83.07 | 82.53 | 82.33 | 76.53 | 70.68 | 64.19 |
| Total Liabilities & Stockholders Equity | 108.69 | 106.59 | 114.33 | 106.41 | 98.14 | 91.53 |
| Book Value Per Share | 1.05 | 1.05 | 1.04 | 0.96 | 0.89 | 0.81 |
| Tangible Book Value Per Share | 0.99 | 0.98 | 0.97 | 0.89 | 0.88 | 0.80 |
| Full-Time Employees | - | - | - | 117 | - | - |
| Price to Book Ratio | 1.99 | 3.08 | 4.59 | 7.17 | 11.57 | 20.42 |
| Return on Assets | 9.90 | 16.14 | 19.05 | 19.90 | 26.42 | 24.36 |
| Return on Equity | 13.32 | 21.80 | 27.07 | 28.35 | 38.90 | 37.36 |
| Return on Invested Capital | -1.39 | 1.15 | 7.53 | 5.27 | 6.29 | 5.43 |
| Quick Ratio | 4.71 | 5.13 | 3.55 | 3.83 | 3.29 | 3.24 |
| Current Ratio | 5.93 | 6.50 | 4.61 | 4.86 | 4.12 | 3.88 |
Cash flow, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 |
|---|---|---|---|---|---|---|
| Net Income | -1.17 | 0.96 | 6.32 | 4.13 | 4.58 | 3.61 |
| Depreciation | 0.29 | 0.29 | 0.29 | 0.86 | 0.20 | 0.20 |
| Other Funds (Non Cash) | 1.84 | 1.99 | -2.68 | -0.70 | 1.92 | 1.74 |
| Funds from Operations | 0.96 | 3.24 | 3.92 | 4.29 | 6.70 | 5.55 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 1.67 | -0.47 | -5.12 | -3.67 | -3.00 | -4.30 |
| Cash from Operating Activities | 2.62 | 2.77 | -1.19 | 0.62 | 3.69 | 1.24 |
| Capital Expenditures | -0.05 | -0.09 | -0.06 | -0.10 | -0.02 | -0.14 |
| Net Assets From Acquisitions | 0.00 | -0.00 | -0.49 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 5.80 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.05 | -0.09 | 5.25 | -0.10 | -0.02 | -0.14 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.20 | -2.49 | -2.24 | -0.02 | 0.15 | 3.75 |
| Repurchase of Common Pref Stock | 0.00 | -2.77 | -2.35 | -0.25 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.20 | 0.28 | 0.11 | 0.23 | 0.15 | 3.75 |
| Proceedsfrom Stock Options | -0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | -0.05 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | -0.05 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 0.20 | -2.49 | -2.29 | -0.03 | 0.15 | 3.75 |
| Net Change in Cash | 2.77 | 0.19 | 1.76 | 0.50 | 3.82 | 4.86 |
| Free Cash Flow | 2.57 | 2.68 | -1.25 | 0.52 | 3.67 | 1.11 |
| Price to Free Cash Flow | 51.09 | 46.84 | 92.20 | 40.86 | 38.31 | 59.52 |
Revenue breakdown
| United States | 2024: 99.60M 2025: 129.42M |
|---|---|
| Analytical Reference Standards and Services | 2024: 3.01M 2025: 3.08M |
| Consumer Products | 2024: 76.77M 2025: 97.67M |
| Ingredients | 2024: 19.81M 2025: 28.68M |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 8.36% | 4.3M | 52.0M | 536.37K |
| 2026-10-15 | 8.04% | 4.2M | 52.0M | 560.74K |
| 2026-09-30 | 7.46% | 3.9M | 52.0M | 568.49K |
| 2026-09-15 | 7.69% | 4.0M | 52.0M | 634.19K |
| 2026-08-31 | 7.97% | 4.2M | 52.1M | 681.50K |
| 2026-08-14 | 8.27% | 4.3M | 52.1M | 775.66K |
| 2026-07-31 | 8.72% | 4.5M | 52.1M | 845.89K |
| 2026-07-15 | 9.12% | 4.8M | 52.5M | 858.16K |
| 2026-06-30 | 8.37% | 4.4M | 52.5M | 834.10K |
| 2026-06-15 | 8.57% | 4.5M | 52.5M | 919.05K |
| 2026-05-29 | 8.96% | 4.7M | 52.6M | 1.22M |
| 2026-05-15 | 9.48% | 5.0M | 52.6M | 1.22M |
| 2026-04-30 | 10.26% | 5.4M | 52.6M | 1.16M |
| 2026-04-15 | 10.30% | 5.5M | 52.9M | 1.18M |
| 2026-03-31 | 10.40% | 5.5M | 52.9M | 1.23M |
| 2026-03-13 | 10.56% | 5.6M | 52.9M | 1.14M |
| 2026-02-27 | 12.22% | 6.5M | 52.9M | 832.18K |
| 2026-02-13 | 12.33% | 6.5M | 52.7M | 807.70K |
| 2026-01-30 | 11.27% | 5.9M | 52.7M | 863.07K |
| 2026-01-15 | 11.01% | 5.8M | 52.7M | 891.38K |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 2.50 | 0.00 | 4.90 | 0.15 | 1.299 | 401 | 0.00 | 0.225 | -0.007 | 0.001 |
| call | 5.00 | 0.00 | 0.05 | 0.02 | 3.392 | 2,188 | 0.00 | 0.108 | -0.011 | 0.001 |
| call | 7.50 | 0.00 | 0.05 | 0.05 | 4.688 | 531 | 0.00 | 0.090 | -0.014 | 0.001 |
| put | 2.50 | 0.00 | 0.55 | 0.15 | 1.784 | 303 | 0.00 | -0.775 | -0.007 | 0.001 |
| put | 5.00 | 2.30 | 3.50 | 2.45 | 8.650 | 9.00 | 0.00 | -0.892 | -0.012 | 0.001 |
| put | 7.50 | 4.80 | 6.00 | 3.46 | 10.037 | 0.00 | 0.00 | -0.910 | -0.014 | 0.001 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-04 | 8-K | Current report | 2026-11-04 | SEC |
| 2026-11-04 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-08-04 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-04 | 8-K | Current report | 2026-08-04 | SEC |
| 2026-07-29 | SCHEDULE 13G | SEC | ||
| 2026-07-10 | 424B5 | SEC | ||
| 2026-07-09 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-07-08 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-30 | SEC |
| 2026-07-08 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-30 | SEC |
| 2026-07-08 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-30 | SEC |
| 2026-06-29 | 8-K | Current report | 2026-06-24 | SEC |
| 2026-06-29 | S-3 | Registration statement for specified transactions by certain issuers including face-amount certificate companies | SEC | |
| 2026-06-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-24 | SEC |
| 2026-06-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-24 | SEC |
| 2026-06-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-24 | SEC |
| 2026-06-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-24 | SEC |
| 2026-06-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-24 | SEC |
| 2026-06-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-24 | SEC |
| 2026-06-26 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-24 | SEC |
| 2026-05-06 | 8-K | Current report | 2026-05-06 | SEC |
| 2026-05-06 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-04-29 | ARS | Annual report to security holders. | 2025-12-31 | SEC |
| 2026-04-29 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-04-29 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-06-24 | SEC |
| 2026-04-27 | 4 | Statement of changes in beneficial ownership of securities | 2026-04-24 | SEC |
| 2026-03-19 | 8-K | Current report | 2026-03-19 | SEC |
| 2026-03-04 | 8-K | Current report | 2026-03-04 | SEC |
| 2026-03-04 | 10-K | Annual report pursuant to Section 13 or 15(d) | 2025-12-31 | SEC |
| 2026-02-26 | 8-K | Current report | 2026-02-24 | SEC |
| 2026-02-24 | 4 | Statement of changes in beneficial ownership of securities | 2026-02-19 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 45.62K | 2 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| BlackRock, Inc. | 5.25% |
| SteelPeak Wealth, LLC | 4.52% |
| Tieton Capital Management, LLC | 3.12% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.70% |
| Qube Research & Technologies Ltd | 2.04% |
| GEODE CAPITAL MANAGEMENT, LLC | 1.82% |
| GOLDMAN SACHS GROUP INC | 1.59% |
| UBS Group AG | 1.47% |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.47% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.46% |
Funds
| Fund | % owned |
|---|---|
| iShares Russell 2000 ETF | 1.87% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 1.85% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.79% |
| Fidelity Small Cap Index Fund | 0.79% |
| VANGUARD CONSUMER STAPLES INDEX FUND | 0.75% |
| iShares Russell 2000 Growth ETF | 0.68% |
| VANGUARD RUSSELL 2000 INDEX FUND | 0.42% |
| Fidelity Extended Market Index Fund | 0.36% |
| Victory Small Cap Stock Fund | 0.35% |
| Schwab U.S. Small-Cap ETF | 0.33% |
OakChart. NAGE. Cached 15 minutes.